UiPath shares have rebounded from a steep 2026 slide after the automation firm posted its first GAAP profit and repositioned around AI agents.

UiPath's Daniel Dines says AI has no taste, agents can't fix messy processes fast, and bosses cutting staff blindly destroy value they never measured.

Discover how automation, AI, and organoid technologies are improving drug discovery through scalable workflows.

IU Health has a new lab for 3D-printing model organs. The models help clinicians plan surgeries, communicate with patients ...

PATH's AI orchestration push and growing enterprise adoption make it a more compelling buy over NU despite Nubank's strong ...

Trupeer AI, the workflow knowledge layer for teams and AI agents, today announced the appointment of Raghu Subramanian as President and Chief Business Officer, as the company accelerates its next ...

Is PATH a good stock to buy? We came across a bullish thesis on UiPath, Inc. on Montana Insights’s Substack by Montana Matos. In this article, we will summarize the bulls’ thesis on PATH. UiPath, Inc.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

UiPath is delivering accelerating revenue growth and rising ARR, benefiting from the broader AI-driven business transformation. Despite a strong Q1 beat-and-raise, PATH shares remain down ~30% YTD, ...

UiPath announced that One NZ has set a new benchmark for enterprise service delivery across ANZ using UiPath Maestro.